NCT00372372已完成4 期
The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- bone mineral density
研究概览
简要总结
The efficacy of risedronate in prevention of bone loss in patients receiving high dose corticosteroid treatment
详细描述
We compare the effect of risedronate with placebo in bone mineral density changes in patients receiving high dose corticosteroids for their underlying diseases
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with various medical conditions who require high dose glucocorticoid treatment: (1) pulse methylprednisolone; (2) oral prednisolone (>=0.8mg/kg/day) or equivalent for at least 6 weeks.
- •Age>=18 years and <75 years.
排除标准
- •Pregnant or lactating women.
- •Uncorrected hypocalcemia.
- •History of esophageal stricture.
- •Previous intolerance or hypersenstivity to biphosphonates.
结局指标
主要结局
bone mineral density
次要结局
- Adverse events, new vertebral fractures
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Can risedronate prevent periprosthetic bone loss after hip arthroplasty?A randomized, double-blind, placebo-controlled trial - PREVENTPeriprosthetic bone loss after total hip arthroplasty (THA) is the main factor in limiting the longevity of implants used för treatment of osteoarthritis. Bone loss leads to implant destabilization. Bisphosphonates, given for approximately 6 months after THA may prevent this bone loss and lead to longer implant fixation and lower incidence of aseptic prosthetic loosening. We want to perform a clinical trial with risedronate to investigate if we can influence periprosthetic bone loss.EUCTR2004-002965-19-SEOrthopaedic department, Karolinska Institutet, Danderyd's Hospital
已完成
3 期
Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.Acute Spinal Cord Injury.NCT00150696Toronto Rehabilitation Institute38
已完成
4 期
Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip ArthroplastyBone LossNCT00772395Danderyd Hospital78
已完成
2 期
Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of BoneFibrous Dysplasia of BoneNCT00445575Institut National de la Santé Et de la Recherche Médicale, France80
进行中（未招募）
不适用
Effects of generic risedronate on bone turnover markers and bone mineral density in Thai postmenopausal osteoporosis.postmenopausal womenBone turnover markersrisedronateBMDosteoporosisTCTR20240427002Ratchadapisek Research Funds80